10-K/APeriod: FY2011

DEXCOM INC Annual Report (Amendment), Year Ended Dec 31, 2011

Filed May 15, 2012For Securities:DXCM

Summary

This filing is an amendment (No. 2) to DexCom Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The document primarily consists of an extensive exhibit index detailing various agreements, plans, and incorporation by reference from previous filings. It confirms DexCom's status as a large accelerated filer and a non-shell company. Investors should note that the core financial statements and detailed business operations are not present in this specific amendment, which focuses on the exhibits and formal certifications. The filing's purpose is to provide a comprehensive list of supporting documents and confirm adherence to reporting requirements as of the filing date of May 15, 2012. Key details available within this amendment include the registration of common stock and preferred stock purchase rights on the NASDAQ Stock Market, the number of outstanding common shares as of March 26, 2012 (68,534,954), and the market value of non-affiliate shares as of June 30, 2011. The exhibit index reveals a history of significant agreements related to development, licensing, collaboration, and executive compensation, indicating active strategic partnerships and internal management structures.

Key Highlights

  • 1DexCom, Inc. filed Amendment No. 2 to its 2011 Form 10-K on May 15, 2012.
  • 2The company is classified as a large accelerated filer.
  • 3Common stock and preferred stock purchase rights are listed on The NASDAQ Stock Market LLC.
  • 4As of March 26, 2012, there were 68,534,954 shares of common stock outstanding.
  • 5The aggregate market value of non-affiliate common stock held as of June 30, 2011, was approximately $960.5 million.
  • 6The filing contains an extensive exhibit index, including agreements related to licensing, development, collaboration, and executive compensation plans.
  • 7Certain portions of some agreements may have confidential treatment requested and were filed separately with the SEC.

Frequently Asked Questions

This filing is an amendment to DexCom's 2011 Annual Report on Form 10-K. Its main purpose is to provide an updated and comprehensive list of exhibits, including various agreements, plans, and legal documents, some of which are incorporated by reference from prior SEC filings. It also includes updated certifications from the CEO and CFO.

No, this specific filing (Amendment No. 2) is primarily an exhibit index and certification document. The detailed financial statements and performance analysis for the fiscal year ended December 31, 2011, would have been in the original Form 10-K filed prior to this amendment.

The filing includes signatures and indicated roles for Terrance Gregg (Chief Executive Officer and Director), Kevin Sayer (President and Director), and Jess Roper (Chief Financial Officer and Principal Financial and Accounting Officer), along with several other Directors.

The exhibit index reveals that DexCom has engaged in various strategic agreements, including exclusive patent license agreements, collaboration agreements, joint development agreements, commercialization agreements, and distribution agreements with entities like SM Technologies, LLC, Edwards Lifesciences LLC, Animas Corporation, and Roche Diagnostics Operations, Inc.